Evidence map›Paper›PMID 41700306›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Refining Alzheimer's disease biological diagnosis with plasma biomarkers: Resolving p-tau217 "gray zone" with p-tau181 integration.

Giulia Giacomucci, Silvia Maria Rita Tabbì, Assunta Ingannato, Silvia Bagnoli, Sonia Padiglioni, Chiara Crucitti, Chiara Sensi, Serena Sanesi, Valentina Moschini, Carmen Morinelli and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giulia GiacomucciDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.ORCID https://orcid.org/0000-0002-8711-331X
Silvia Maria Rita TabbìDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.
Assunta IngannatoDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.
Silvia BagnoliDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.
Sonia PadiglioniRegional Referral Centre for Relational Criticalities - Tuscany Region Florence Italy.
Chiara CrucittiDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.
Chiara SensiDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.
Serena SanesiUniversity of Florence Florence Italy.
Valentina MoschiniNeurology Unit, Dipartimento Neuromuscoloscheletrico E Degli Organi Di Senso Careggi University Hospital Florence Italy.
Carmen MorinelliNeurology Unit, Dipartimento Neuromuscoloscheletrico E Degli Organi Di Senso Careggi University Hospital Florence Italy.
Giulia GaldoDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.
Valentina BertiDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio" University of Florence Florence Italy.
Benedetta NacmiasDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.ORCID https://orcid.org/0000-0001-9338-9040
Valentina BessiDepartment of Neuroscience, Psychology, Drug Research and Child Health University of Florence Florence Italy.ORCID https://orcid.org/0000-0002-6176-3584

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBlood-based biomarkers offer a less invasive and more scalable alternative to cerebrospinal fluid (CSF) analysis and amyloid-positron emission tomography (PET) for the biological diagnosis of Alzheimer's disease (AD). Among blood-based biomarkers (BBMs), plasma phosphorylated tau217 (p-tau217) has shown the highest accuracy, although intermediate ("gray zone") values remain challenging to interpret.

methodsIn this study, 401 individuals across the Alzheimer's Disease (AD) continuum (Subjective Cognitive Decline, Mild Cognitive Impairment, and AD dementia) underwent clinical and biomarker assessment. Plasma p-tau217, p-tau181, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured. Core1 status was defined through CSF or amyloid-PET.

resultsPlasma p-tau217 demonstrated the strongest discrimination of Core1 positivity (area under the curve [AUC] = 0.95) and showed the steepest increase with disease progression. A two-cutoff strategy improved diagnostic accuracy (94%), though 18% of patients fell into the gray zone. Within this subgroup, p-tau181 was the only predictor of Core1 status and correctly reclassified 77.4% of indeterminate cases. DISCUSSION: These findings support a sequential plasma biomarkers approach for reliable AD detection.

Indexed as

Alzheimer's diseasemild cognitive impairmentplasma biomarkersplasma GFAPplasma NfLplasma p‐tau181plasma p‐tau217subjective cognitive decline

Identifiers

PMID41700306
PMCPMC12906650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.